T7 RNA POLYMERASE VARIANTS
The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5′)ppp(5′)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.
1 . An engineered RNA polymerase comprising a polypeptide sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to the reference sequence of SEQ ID NOS: 4 and/or 15, or a functional fragment thereof, wherein said engineered RNA polymerase comprises at least one substitution or substitution set in said polypeptide sequence, and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO:4 or 15.
2 . The engineered RNA polymerase of claim 1 , wherein at least one substitution or substitution set said polypeptide sequence comprises a substitution set is selected from 397/513/635, 397/513/635/660, 513/660/664, 513/635/660, 513/635/664, 513/660/664, and 660/664, and/or any combinations thereof, wherein the amino acid positions are numbered with reference to SEQ ID NO: 4.
3 . The engineered RNA polymerase of claim 1 , wherein said polypeptide sequence further comprises at least one substitution or substitution set is selected from 397, 397/513, 397/513/635, 397/513/635, 397/513/635/656, 397/513/635/656/660, 397/513/635/656/660/664, 397/513/635/656/664, 397/513/635/660, 397/513/635/660/664, 397/513/635/664, 397/513/656/660, 397/513/660, 397/513/660/664, 397/513/664, 397/513, 397/635, 397/635/656/660/664, 397/635/656/664, 397/635/660, 397/635/664, 397/635/664/850, 397/660, 397/664, and/or any combinations thereof, wherein the amino acid positions are numbered with reference to SEQ ID NO: 4.
4 . The engineered RNA polymerase of claim 1 , wherein at least one substitution or substitution set is selected from 113/137/513, 136/357/404/514, 136/357/514, 136/394/404/446, 136/401, 136/401/404, 136/404/446, 136/404/514, 136/446, 136/514, 137, 137/401, 137/401/513, 137/401/513, 137/513, 137/513/621, 137/635, 137/656, 357/394/401/404/514, 357/394/446/514, 357/514, 394/446/514, 401/404, 401/404/514, 401/513/635, 401/635, 513/635, 513/635/656, 513/660, 635/656, 635/660, and 660, and/or any combinations thereof, wherein the amino acid positions are numbered with reference to SEQ ID NO: 15.
5 . The engineered RNA polymerase of claim 1 , wherein said engineered RNA polymerase comprises a polypeptide sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered RNA polymerase variant set forth in Table 5.3, 5.4, 5.5, and/or 5.6.
6 . The engineered RNA polymerase of claim 1 , wherein said engineered RNA polymerase comprises a variant engineered polymerase provided in Table 5.3, 5.4, 5.5, and/or 5.6.
7 . The engineered RNA polymerase of claim 1 , wherein said engineered RNA polymerase comprises a polypeptide sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered RNA polymerase variant set forth in SEQ ID NO: 4, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and/or 39.
8 . The engineered RNA polymerase of claim 1 , wherein said engineered RNA polymerase comprises a variant engineered polymerase set forth in SEQ ID NO: 4, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, or 37, or 39.
9 . The engineered RNA polymerase of claim 1 , wherein said engineered polymerase exhibits at least one improved property compared to wild-type T7 RNA polymerase.
10 . The engineered RNA polymerase of claim 9 , wherein said at least one improved property is selected from improved selectivity for cap analog relative to GTP during transcription initiation, improved protein expression, improved stability in storage buffer, and improved stability under reaction conditions.
11 . The engineered RNA polymerase of claim 1 , wherein the polymerase maintains RNA yield, transcription fidelity, thermostability, protein expression, stability at −20° C., or stability in reaction conditions equivalent to the wild-type T7 RNA polymerase.
12 . The engineered RNA polymerase of claim 1 , wherein said RNA polymerase generates greater than about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more capped RNA transcripts relative to uncapped transcripts.
13 . The engineered RNA polymerase of claim 12 , wherein said RNA polymerase generates greater than 90% capped RNA transcripts relative to uncapped transcripts.
14 . The engineered RNA polymerase of claim 1 , wherein said engineered polymerase is purified.
15 . A polynucleotide sequence encoding at least one engineered RNA polymerase of claim 1 .
16 . A polynucleotide sequence encoding at least one engineered RNA polymerase comprising at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to the reference sequence of SEQ ID NO: 4 and/or 15, or a functional fragment thereof, wherein said engineered RNA polymerase comprises at least one substitution at one or more amino acid positions.
17 . A polynucleotide sequence encoding at least one engineered RNA polymerase comprising at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity to SEQ ID NO: 4, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, and/or 39, or a functional fragment thereof.
18 . A polynucleotide sequence encoding at least one engineered RNA polymerase, wherein said polynucleotide sequence comprises at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more sequence identity SEQ ID NO: 3, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, and/or 38.
19 . The polynucleotide sequence of claim 18 , wherein said polynucleotide sequence is operably linked to a control sequence.
20 . The polynucleotide sequence of claim 18 , wherein said polynucleotide sequence is codon optimized.
21 . An expression vector comprising at least one polynucleotide sequence of claim 18 .
22 . A host cell comprising at least one expression vector of claim 21 .
23 . A method of producing an engineered RNA polymerase in a host cell, comprising culturing the host cell of claim 22 , under suitable culture conditions, such that at least one engineered RNA polymerase is produced.
24 . The method of claim 23 , further comprising recovering at least one engineered RNA polymerase.
25 . The method of claim 23 ,l further comprising the step of purifying said at least one engineered RNA polymerase.
26 . A composition comprising at least one engineered RNA polymerase of claim 1 .
27 . A method for producing substantially capped mRNA, comprising performing an in vitro transcription reaction utilizing an engineered RNA polymerase.
28 . The method of claim 27 , wherein said engineered RNA polymerase generates greater than about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more capped RNA transcripts relative to uncapped transcripts.
29 . The method of claim 28 , wherein said engineered RNA polymerase generates greater than 90% or more capped RNA transcripts relative to uncapped transcripts.
30 . The method of claim 29 , wherein said engineered RNA polymerase generates greater than 95% or more capped RNA transcripts relative to uncapped transcripts.
31 . A method for producing capped RNA transcripts, comprising providing a composition comprising: i) at least one engineered RNA polymerase of claim 1 , a dinucleotide cap analog, and ii) a DNA template; exposing said DNA template to said composition under conditions such that said engineered RNA polymerase produces a capped RNA transcript.
32 . The method of claim 31 , where the dinucleotide cap analog is alpha, gamma-bis(N7-methylguanosine) triphosphate (m7G(5′)ppp(5′)m7G) or an anti-reverse cap analog 3′-O-Me-m1G(5′)ppp(5′) G.
33 . The method of claim 32 , wherein the dinucleotide cap analog is alpha, gamma-bis (N7-methylguanosine) triphosphate.
34 . The method of claim 31 , wherein said engineered RNA polymerase generates greater than about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more capped RNA transcripts relative to uncapped transcripts.
35 . The method of claim 31 , wherein said engineered RNA polymerase generates greater than 90% or more capped RNA transcripts relative to uncapped transcripts.
36 . The method of claim 35 , wherein said engineered RNA polymerase generates greater than 95% or more capped RNA transcripts relative to uncapped transcripts.
37 . The method of claim 36 , wherein said method comprises an in vitro transcription reaction.
38 . The method of claim 31 , further comprising the addition of inorganic pyrophosphatase.